Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
about
Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studiesMeta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaMRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and DiagnosisAnxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis.Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.Enrichment and stratification for predementia Alzheimer disease clinical trials.Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 CarriersCerebrospinal Aβ11-x and 17-x levels as indicators of mild cognitive impairment and patients' stratification in Alzheimer's disease.Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's diseaseClinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's diseaseOxidative Stress and Its Clinical Applications in DementiaCerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis.Injury markers predict time to dementia in subjects with MCI and amyloid pathologyUpcoming candidate cerebrospinal fluid biomarkers of Alzheimer's diseaseFluid biomarkers in Alzheimer's disease - current conceptsAre CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical SettingApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.Risk factors for the progression of mild cognitive impairment to dementia.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort.Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial DesignCurrently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
P2860
Q26798325-5B91A14A-2AAE-43FF-B31D-E0AD3A149C0BQ26864063-1C98ADF9-9681-483D-A028-E748F862D2F6Q33650376-30633B84-6C69-476B-B879-B571D6B80C25Q33924292-9DE8D534-817A-44D4-B7BD-901803CF5DAFQ34349522-7BC89BEA-CA8C-4BE6-94BB-2687C7E14A8FQ34364619-5E32A90C-3297-44CE-8AE4-867166DC1B2EQ34452239-180C0986-2BED-4B2E-BA6E-06E8C0B3852CQ34468797-6777A494-08CA-4A75-9B39-FC976828ADCDQ34824216-FD860EAE-9D57-45A2-8F98-C41DE2F4D610Q35106997-A890FBF0-C9FD-4FBA-BDF5-43ED01B37DCBQ35284971-8F07D256-8BBB-4ACF-A325-32657BC04C9FQ35623258-A5E05EFE-3709-4751-A71C-F6D9FB837391Q35750755-FB02E475-7A43-4AAD-AFAC-AAE421E86296Q36330912-2BC83F3C-12D7-47A6-9556-B41DA342CFEFQ36337525-AA49EA66-748A-4BD7-90E3-B76381619F98Q36953503-61449779-FDC4-42CF-A63D-DEECADD3E02AQ37387826-B714C5FD-EFC0-4B77-8A1C-4CCA268FCB55Q37634708-5D8E0B25-5248-4C98-AFA4-D5B0F3A62941Q38149355-9ADC13F1-16E2-4749-A857-79CBE1E495A7Q38830945-8BE3A9D2-367F-40F1-A419-73F0460025B5Q40311890-FF43097B-261A-43F7-8104-C98C765F2544Q40824989-4AA85C89-C6B6-46B1-8718-20066633D488Q42374123-1C6A5242-1EA9-46EE-BD2C-5AB88E2F4DCDQ47429580-7C405ACD-CF30-4DAF-973E-BF925B9EE1DBQ47604596-36EDDD69-8A91-412F-A690-D3F138EB76D3Q59049398-B5DEB0FC-9C0A-4BB9-ABD6-0FE3DFD78515Q59052213-B91E7D63-5748-4CA3-A4F4-E0D184DEC296
P2860
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
@en
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
@nl
type
label
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
@en
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
@nl
prefLabel
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
@en
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
@nl
P2093
P50
P1476
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
@en
P2093
Frans Verhey
Gilbert L'Italien
Ineke van Rossum
Leah Burns
Pauline Aalten
Pieter Jelle Visser
Robin Wolz
Stephanie Vos
P304
P356
10.1016/J.NEUROBIOLAGING.2011.12.017
P50
P577
2012-01-20T00:00:00Z